Xueping Li

Jan 9, 2025 | onlinelibrary.wiley.com | Ting Chen |Xueping Li |Yi Li |Lu Zhang

1 Introduction Hepatocellular carcinoma (HCC) ranks as the sixth most commonly diagnosed cancer and the third leading cause of cancer-related mortality worldwide.[1] Due to the insidious nature of HCC, most patients are often diagnosed at advanced stages and are only eligible to systemic treatments.[2] Despite the evolution of molecular-targeted therapy and immunotherapy has dramatically changed the systemic treatment landscape of advanced HCC, the overall response is still limited by the...